ECSP972123A - COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 - - Google Patents

COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 -

Info

Publication number
ECSP972123A
ECSP972123A ECSP972123A ECSP972123A EC SP972123 A ECSP972123 A EC SP972123A EC SP972123 A ECSP972123 A EC SP972123A EC SP972123 A ECSP972123 A EC SP972123A
Authority
EC
Ecuador
Prior art keywords
cyclooxygenase
compound
directed
treatment
composition
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Bruno Hancock
Conrad Winters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP972123 priority Critical patent/ECSP972123A/en
Publication of ECSP972123A publication Critical patent/ECSP972123A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención está dirigida a una composición farmacéutica para el tratamiento de enfermedades en las que interviene la ciclooxigenasa-2- siendo tal composición apropiada para la administración una vez al día, comprendiendo dicha composición un compuesto inhibidor de la ciclooxigenasa-2, caracterizado por una gran potencia, una larga vida promedio y un alto grado de especificidad para inhibir la ciclooxigenasa-2 con más preferencia que la ciclooxigenasa-1. Tal compuesto está especificado por 3-fenil-4-(4-metilsulfonil)fenil-2-(5H)-furanona. En un aspecto está invención está dirigida a una composición farmacéutica para el tratamiento de enfermedades en las que interviene la cilooxigenasa-2 siendo dicha composición apropiada para administración oral una vez al día comprendiendo dicha composición de 1 a 125 mgs del compuesto arriba indicado. La invención está también dirigida a un método para tratar enfermedades en las que interviene la ciclooxigenasa-2 que comprende la administración oral una vez al día de 5 a 125 mgs del compuesto arriba indicado. La invención está también dirigida a un método para tratar enfermedades en las que interviene la ciclooxigenasa-2, que comprende la administración oral una vez al día de 5 a 125 mgs del compuesto arriba indicado. La invención está también dirigida al uso del compuesto arriba indicado en la elaboración de un medicamento que contiene de 5 a 125 mgs de dicho compuesto para administración una vez al día, para el tratamiento de enfermedades en la que interviene la cilooxigenasa-2.This invention is directed to a pharmaceutical composition for the treatment of diseases in which cyclooxygenase-2 is involved, such composition being appropriate for once-daily administration, said composition comprising a cyclooxygenase-2 inhibitor compound, characterized by a great Potency, long average life and a high degree of specificity to inhibit cyclooxygenase-2 more preferably than cyclooxygenase-1. Such a compound is specified by 3-phenyl-4- (4-methylsulfonyl) phenyl-2- (5H) -furanone. In one aspect, this invention is directed to a pharmaceutical composition for the treatment of diseases in which ciloxygenase-2 is involved, said composition being suitable for oral administration once a day, said composition comprising from 1 to 125 mgs of the compound indicated above. The invention is also directed to a method of treating diseases involving cyclooxygenase-2, comprising once daily oral administration of 5 to 125 mgs of the above compound. The invention is also directed to a method of treating diseases involving cyclooxygenase-2, which comprises once daily oral administration of 5 to 125 mgs of the above compound. The invention is also directed to the use of the compound indicated above in the manufacture of a medicine containing from 5 to 125 mgs of said compound for once-daily administration, for the treatment of diseases involving ciloxygenase-2.

ECSP972123 1997-05-16 1997-05-16 COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 - ECSP972123A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP972123 ECSP972123A (en) 1997-05-16 1997-05-16 COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 -

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP972123 ECSP972123A (en) 1997-05-16 1997-05-16 COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 -

Publications (1)

Publication Number Publication Date
ECSP972123A true ECSP972123A (en) 1998-04-24

Family

ID=42042954

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP972123 ECSP972123A (en) 1997-05-16 1997-05-16 COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 -

Country Status (1)

Country Link
EC (1) ECSP972123A (en)

Similar Documents

Publication Publication Date Title
AR012014A1 (en) COMPOSITIONS FOR TREATMENT OF A DAY OF DISEASES MEDIATED BY CYCLOOXYGENASE-2
NO962187D0 (en) Compositions that inhibit apoptosis, methods of purifying the compositions and their use
EE03969B1 (en) (Methylsulfonyl) phenyl-2- (5H) -furanones, their Use and Pharmaceutical Compositions
PT951474E (en) NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PT948527E (en) NEW CYCLOSPORAN DERIVATIVES HIS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ES2193337T3 (en) USE OF STRONTIUM SALTS FOR THE TREATMENT OF ARTROSIS.
DK0828724T3 (en) 5-oxygenated diaryl-2- (5H) -furanones as COX-2 inhibitors
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
PT951473E (en) NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
BR9812753A (en) Pharmaceutical combination, use thereof, process for treating an inflammatory disease, and pharmaceutical composition
PT1259512E (en) PTERIDIN COMPOUNDS FOR PSORIASIS TREATMENT
UA41297C2 (en) INDOLA DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
CY1113191T1 (en) COMPOSITION OF COMPACTED EFFECTIVE DISCS
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
UY24308A1 (en) BINDER-FREE TABLETS CONTAINING TRAMADOL OR A SALT OF TRAMADOL, FOR ORAL ADMINISTRATION
NO983530D0 (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
NO20040907L (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its use as a pain reliever
DK0663835T3 (en) Use of parathormone, its biologically active fragments and related peptides for the treatment of pregnancy
DK0614456T3 (en) 1alpha, 24 (S) -dihydroxy vitamin D2, its preparation and use
BR9608392A (en) Multiparticulate controlled-release preparation and tablet dosage form.
NO982229D0 (en) Sulfur-containing di-tert-butylphenol compounds useful as anti-inflammatory agents
MX9300558A (en) NEW SULFONILUREA, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL FORMULATION THAT CONTAINS IT.
BR0108980A (en) Pharmaceutical application and formulation comprising norepinephrine reuptake inhibitor
ECSP972123A (en) COMPOSITIONS FOR ONLY ONE TREATMENT OF DISEASES INVOLVING CYCLOOXYGENASE- 2 -